Literature DB >> 11435294

Clinical and virologic characteristics of chronic active Epstein-Barr virus infection.

H Kimura1, Y Hoshino, H Kanegane, I Tsuge, T Okamura, K Kawa, T Morishima.   

Abstract

Thirty patients with chronic active Epstein-Barr virus (CAEBV) infection were analyzed. The study group included 18 male and 12 female patients, ranging in age from 5 to 31 years with a mean age of 14.2 years. Not all patients had high titers of EBV-specific antibodies, but all patients had high viral loads in their peripheral blood (more than 10(2.5) copies/microg DNA). Fifty percent of the patients displayed chromosomal aberrations, and 79% had monoclonality of EBV. Patients were divided into 2 clinically distinct groups, based on whether the predominantly infected cells in their peripheral blood were T cells or natural killer (NK) cells. Over a 68-month period of observation, 10 patients died from hepatic failure, malignant lymphoma, or other causes. Patients with T-cell CAEBV had a shorter survival time than those with NK-cell type of disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435294     DOI: 10.1182/blood.v98.2.280

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  100 in total

Review 1.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.

Authors:  J Ogawa; M Harigai; T Akashi; K Nagasaka; F Suzuki; S Tominaga; N Miyasaka
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

3.  Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis.

Authors:  Ayako Arai; Ken-Ichi Imadome; Yuko Watanabe; Mayumi Yoshimori; Takatoshi Koyama; Takeharu Kawaguchi; Chiaki Nakaseko; Shigeyoshi Fujiwara; Osamu Miura
Journal:  Int J Hematol       Date:  2011-04-14       Impact factor: 2.490

Review 4.  Spectrum of Epstein-Barr virus-related diseases: a pictorial review.

Authors:  Eriko Maeda; Masaaki Akahane; Shigeru Kiryu; Nobuyuki Kato; Takeharu Yoshikawa; Naoto Hayashi; Shigeki Aoki; Manabu Minami; Hiroshi Uozaki; Masashi Fukayama; Kuni Ohtomo
Journal:  Jpn J Radiol       Date:  2009-02-08       Impact factor: 2.374

5.  An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection.

Authors:  Chongfeng Xu; Junhong Ai; Qingxun Zhang; Ting Li; Xiaorong Wu; Zhengde Xie; Ziyuan Duan
Journal:  J Vis Exp       Date:  2018-03-30       Impact factor: 1.355

6.  Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with chronic active Epstein-Barr virus infection.

Authors:  Kenji Tamayose; Motoki Egashira; Koichi Sugimoto; Jun Ando; Shigeo Mori; Kazuo Oshimi
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

7.  Biclonal expansion of T cells infected with monoclonal Epstein-Barr virus (EBV) in a patient with chronic, active EBV infection.

Authors:  S Toyabe; W Harada; M Uchiyama
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 8.  Viral-associated lymphoid proliferations.

Authors:  Stefania Pittaluga
Journal:  Semin Diagn Pathol       Date:  2013-03-26       Impact factor: 3.464

9.  Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.

Authors:  J I Cohen; H Kimura; S Nakamura; Y-H Ko; E S Jaffe
Journal:  Ann Oncol       Date:  2009-06-10       Impact factor: 32.976

10.  Cardiovascular complications associated with chronic active Epstein-Barr virus infection.

Authors:  Jun Muneuchi; Shouichi Ohga; Masataka Ishimura; Kazuyuki Ikeda; Kenichiro Yamaguchi; Akihiko Nomura; Hidetoshi Takada; Yasunobu Abe; Toshiro Hara
Journal:  Pediatr Cardiol       Date:  2009-01-30       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.